These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Variation in the Serotonin Transporter Gene and Alcoholism: Risk and Response to Pharmacotherapy. Thompson MD; Kenna GA Alcohol Alcohol; 2016 Mar; 51(2):164-71. PubMed ID: 26311211 [TBL] [Abstract][Full Text] [Related]
4. [A pharmacogenetic analysis of dopaminergic and opioidergic genes in opioid addicts treated with the combination of naltrexone and guanfacine]. Kibitov АО; Krupitsky ЕМ; Blokhina ЕА; Verbitskaya ЕV; Brodyansky VМ; Alekseeva NP; Bushara NМ; Yaroslavtseva ТS; Palatkin VY; Masalov DV; Burakov АМ; Romanova ТN; Sulimov GY; Grinenko AY; Kosten Т; Nielsen D; Zvartau EE Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(11. Vyp. 2):36-48. PubMed ID: 28300812 [TBL] [Abstract][Full Text] [Related]
5. Opioid and Dopamine Genes Interact to Predict Naltrexone Response in a Randomized Alcohol Use Disorder Clinical Trial. Anton RF; Voronin KE; Book SW; Latham PK; Randall PK; Glen WB; Hoffman M; Schacht JP Alcohol Clin Exp Res; 2020 Oct; 44(10):2084-2096. PubMed ID: 32772383 [TBL] [Abstract][Full Text] [Related]
6. Genetic moderators of naltrexone's effects on alcohol cue reactivity. McGeary JE; Monti PM; Rohsenow DJ; Tidey J; Swift R; Miranda R Alcohol Clin Exp Res; 2006 Aug; 30(8):1288-96. PubMed ID: 16899031 [TBL] [Abstract][Full Text] [Related]
7. Ondansetron and sertraline may interact with 5-HTTLPR and DRD4 polymorphisms to reduce drinking in non-treatment seeking alcohol-dependent women: exploratory findings. Kenna GA; Zywiak WH; Swift RM; McGeary JE; Clifford JS; Shoaff JR; Fricchione S; Brickley M; Beaucage K; Haass-Koffler CL; Leggio L Alcohol; 2014 Sep; 48(6):515-22. PubMed ID: 25212749 [TBL] [Abstract][Full Text] [Related]
8. Opioid pharmacogenetics of alcohol addiction. Berrettini W Cold Spring Harb Perspect Med; 2013 Jul; 3(7):. PubMed ID: 23729643 [TBL] [Abstract][Full Text] [Related]
9. Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder. Hartwell EE; Feinn R; Morris PE; Gelernter J; Krystal J; Arias AJ; Hoffman M; Petrakis I; Gueorguieva R; Schacht JP; Oslin D; Anton RF; Kranzler HR Addiction; 2020 Aug; 115(8):1426-1437. PubMed ID: 31961981 [TBL] [Abstract][Full Text] [Related]
10. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Anton RF; Oroszi G; O'Malley S; Couper D; Swift R; Pettinati H; Goldman D Arch Gen Psychiatry; 2008 Feb; 65(2):135-44. PubMed ID: 18250251 [TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans. Arias AJ; Gelernter J; Gueorguieva R; Ralevski E; Petrakis IL Am J Addict; 2014; 23(3):288-93. PubMed ID: 24724887 [TBL] [Abstract][Full Text] [Related]
12. Study suggests gene may predict success of therapies for alcohol dependence. Kuehn BM JAMA; 2011 Mar; 305(10):984-5. PubMed ID: 21386072 [No Abstract] [Full Text] [Related]
13. Pharmacogenetics of alcoholism: a clinical neuroscience perspective. Ray LA; Courtney KE; Bujarski S; Squeglia LM Pharmacogenomics; 2012 Jan; 13(2):129-32. PubMed ID: 22256863 [No Abstract] [Full Text] [Related]
14. Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues. Schacht JP; Anton RF; Voronin KE; Randall PK; Li X; Henderson S; Myrick H Neuropsychopharmacology; 2013 Feb; 38(3):414-22. PubMed ID: 23032071 [TBL] [Abstract][Full Text] [Related]
16. The role of the Asn40Asp polymorphism of the mu opioid receptor gene (OPRM1) on alcoholism etiology and treatment: a critical review. Ray LA; Barr CS; Blendy JA; Oslin D; Goldman D; Anton RF Alcohol Clin Exp Res; 2012 Mar; 36(3):385-94. PubMed ID: 21895723 [TBL] [Abstract][Full Text] [Related]
17. COMBINE genetics study: the pharmacogenetics of alcoholism treatment response: genes and mechanisms. Goldman D; Oroszi G; O'Malley S; Anton R J Stud Alcohol Suppl; 2005 Jul; (15):56-64; discussion 33. PubMed ID: 16223057 [TBL] [Abstract][Full Text] [Related]
18. Alcohol addiction and the mu-opioid receptor. Berrettini W Prog Neuropsychopharmacol Biol Psychiatry; 2016 Feb; 65():228-33. PubMed ID: 26226591 [TBL] [Abstract][Full Text] [Related]
19. Polymorphisms of the mu-opioid receptor and dopamine D4 receptor genes and subjective responses to alcohol in the natural environment. Ray LA; Miranda R; Tidey JW; McGeary JE; MacKillop J; Gwaltney CJ; Rohsenow DJ; Swift RM; Monti PM J Abnorm Psychol; 2010 Feb; 119(1):115-25. PubMed ID: 20141248 [TBL] [Abstract][Full Text] [Related]
20. Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study. Ray LA; Hutchison KE Arch Gen Psychiatry; 2007 Sep; 64(9):1069-77. PubMed ID: 17768272 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]